Invited webinar -Senolytics to eliminate senescent cells: promising strategy to...- by Dr. Johannes Grillari Evercyte

"Senolytics to eliminate senescent cells: promising strategy to improve tissue regeneration" presented by Dr. Johannes Grillari Evercyte, Ludwig Boltzmann Institute for Traumatology. The Research Center in Cooperation with AUVA, VIenna, Austria; Institute of Molecular Biotechnology, BOKU University, Vienna, Austria; Chaired by Prof. Anna Teti, DISCAB, University of L’Aquila.

With age, senescent cells accumulate in various tissues, which is causatively linked to a state of low-grade chronic inflammation, aging and age-related diseases. As a possible therapy for age-related diseases, the pharmacological ablation of senescent cells using senolytics was proven to be efficient in numerous preclinical disease models and first clinical pilot studies are ongoing. The herein used first generation senolytics, targeting senescent cell anti-apoptotic pathways (SCAPs), are mainly repurposed drugs that lack efficacy, selectivity and often have an unfavorable safety profile. Recently, we discovered an alternative target pathway for the development of novel senolytic compounds that is based on an altered…